Compare Synopsys, Inc. (SNPS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs GeneDx Holdings Corp — how do they compare? Synopsys, Inc. trades at $509.99 (market cap $95.39B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Synopsys, Inc. is far larger — about 47.2× GeneDx Holdings Corp's market cap, and Synopsys, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and GeneDx Holdings Corp for 19 Days on average.
| SNPS | WGS | |
|---|---|---|
Market Cap | $95.39B | $2.02B |
Volume | 3,374,903 | 734,640 |
Sector | Technology | Health |
52-Week High | $534.56 | $167.51 |
52-Week Low | $367.70 | $34.51 |
Typical Hold Time | 71 Days | 19 Days |
Enterprise Value | $102.62B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $497.75, down 0.98% on the day, but maintains a strong bullish technical trend with support at $492. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.91 exceeding the $3.67 estimate. Recent investor day announcements highlighted AI partnerships with OpenAI and Amazon, driving a 13% stock surge and raising long-term growth expectations. Valuation metrics show a high P/E of 86.87, reflecting premium pricing for growth prospects.
The outlook for SNPS is positive, fueled by AI-driven demand for chip design software and strategic acquisitions like Ansys. Investment opportunities include exposure to the expanding custom silicon market and recurring revenue growth. Key risks involve elevated valuation multiples, integration challenges from acquisitions, and competitive pressures in the EDA software space. Analyst consensus is strongly bullish with a $572.54 price target, indicating 15% upside potential.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
